FDA Clears da Vinci 5 for Cardiac Use as Q1 Revenue Jumps 18.8%
FDA cleared Intuitive Surgical’s da Vinci 5 system for advanced cardiac procedures, unlocking a multi-billion-dollar market and bolstering its consumables revenue tail. The company delivered $2.87 billion in quarterly revenue (+18.8% YoY) and $2.53 EPS, outperforming estimates and prompting multiple buy-rating upgrades.
1. Institutional and Hedge Fund Accumulation
During the third quarter, multiple institutional investors boosted their stakes in Intuitive Surgical. Alpha Cubed Investments LLC increased its position by 13.0%, acquiring an additional 10,677 shares to hold 92,600 shares valued at $41.41 million, representing 1.4% of its portfolio and ranking ISRG as its 19th largest holding. Valley Wealth Managers Inc. raised its stake by 52.7% to 4,084 shares, Tandem Investment Advisors Inc. added 396 shares for a 4.5% increase to 9,219 shares, Strategic Advisors LLC lifted its holdings by 63.3% to 10,397 shares, AE Wealth Management LLC boosted its position by 18.9% to 11,556 shares, and LRI Investments LLC grew its stake by 24.0% to 1,997 shares. Institutional investors now own 83.64% of the company’s shares.
2. Quarterly Earnings Outperformance and Profitability Metrics
In its latest quarterly results, Intuitive Surgical reported revenue of $2.87 billion, surpassing consensus estimates of $2.72 billion and marking year-over-year growth of 18.8%. Earnings per share were $2.53, beating the consensus estimate of $2.27 by $0.26. The company achieved a net margin of 28.38% and a return on equity of 15.06%. On the back of these results, analysts project full-year earnings per share of approximately $6.43.
3. Regulatory Expansion and Analyst Momentum
The U.S. Food and Drug Administration granted clearance for the da Vinci 5 system in select advanced cardiac procedures, expanding its addressable market and creating a long-term revenue tail for both systems and consumables. Sell-side support remains robust: TD Cowen initiated coverage with a strong-buy recommendation, Barclays reaffirmed its buy rating, and HSBC issued a bullish outlook on price appreciation. Active growth-oriented managers such as Polen Capital have highlighted Intuitive Surgical as a core holding, reinforcing investor conviction in the company’s long-term prospects.
4. Insider Selling Activity
Intuitive Surgical insiders have executed significant share sales over the past quarter. Director Gary S. Guthart disclosed sales of 24,500 shares and an additional 2,800 shares, while executive vice president Myriam Curet sold 230 shares. Senior vice president Mark Brosius sold 4,500 shares at an average price of $547.36 for a total of $2.46 million, and EVP Henry L. Charlton disposed of 13,731 shares at $580.00 per share for a total of $7.96 million. In total, insiders sold 75,557 shares valued at approximately $42.0 million, representing 0.70% of shares outstanding.